Cover Image
市場調查報告書

絲胺酸/蘇氨酸蛋白激酶A-Raf:開發中產品分析

Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365756
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
絲胺酸/蘇氨酸蛋白激酶A-Raf:開發中產品分析 Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 39 Pages
簡介

本報告提供以絲胺酸/蘇氨酸蛋白激酶A-Raf為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

絲胺酸/蘇氨酸蛋白激酶A-Raf 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發作的企業

  • Basilea Pharmaceutica AG
  • Eli Lilly and Company
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Redx Pharma Plc

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0204TDB

Summary

Global Markets Direct's, 'Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1)
  • The report reviews Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Overview
  • Therapeutics Development
    • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Stage of Development
    • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Therapy Area
    • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Indication
  • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Products under Development by Companies
  • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • Basilea Pharmaceutica AG
    • Eli Lilly and Company
    • Millennium Pharmaceuticals, Inc.
    • Novartis AG
    • Redx Pharma Plc
  • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Drug Profiles
    • BAL-3833 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LXH-254 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3009120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-580 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Dormant Projects
  • Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) - Featured News & Press Releases
    • Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting
    • Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting
    • Apr 22, 2015: Deciphera Pharmaceuticals Presents Data Highlighting pan-RAF inhibitor Cetuximab including Proprietary and Partnered Programs at AACR 2015 Annual Meeting
    • Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY3009120 at AACR Annual Meeting 2015
    • Apr 07, 2014: Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120
    • Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors
    • Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
    • Sep 07, 2004: Biogen Idec And Sunesis Form Collaboration To Discover And Develop Multiple Small Molecule Oncology Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Pipeline by Eli Lilly and Company, H1 2016
  • Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Redx Pharma Plc, H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top